Ives NJ et al. (2007) Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 25: 5426–5434
For patients with metastatic melanoma, chemotherapy is the standard of care. Interferon (IFN) and interleukin 2 (IL-2) immunotherapy is active in malignant melanoma, and clinical trial data suggest that combined chemotherapy and immunotherapy (i.e. biochemotherapy) increases response rates; however, the results of these trials have not been consistent. A recent meta-analysis has assessed the effect of biochemotherapy in metastatic melanoma.
The meta-analysis included 18 trials (11 trials of chemotherapy ± IFN and 7 trials of chemotherapy ± IFN and IL-2) involving 2,621 patients. Overall, 2,039 deaths and 555 responses were reported. Biochemotherapy clearly improved partial response (odds ratio [OR] 0.66; P = 0.0001), complete response (OR 0.50; P = 0.0003), and overall response (OR 0.59; P <0.00001) rates. Overall response was increased significantly in both IFN (OR 0.60; P = 0.0002) and IFN plus IL-2 (OR 0.58; P = 0.0001) immunotherapy subgroups. Data from seven trials showed that biochemotherapy delayed the time to disease progression (OR 0.80; P = 0.0001), and there was no evidence of heterogeneity between the groups treated with the different types of immunotherapy (P = 0.5) or between different trials (P = 0.4). By contrast, biochemotherapy did not increase overall survival (OR 0.99; P = 0.9). There was, however, heterogeneity in the treatment effect between the different trials (P = 0.006), but not between the two immunotherapy subgroups (P = 1.0).
These data show that biochemotherapy improves responses rates, but not overall survival, in patients with metastatic melanoma.
Rights and permissions
About this article
Cite this article
Biochemotherapy improves response rates but not survival in metastatic melanoma. Nat Rev Clin Oncol 5, 125 (2008). https://doi.org/10.1038/ncponc1064
Issue Date:
DOI: https://doi.org/10.1038/ncponc1064